2018
26/10/2018
Safety and efficacy of a hyaluronic acid derivative in the treatment of vulvovaginal atrophy
Fidia farmaceutici announces the results of a prospective clinical investigation aimed at assessing…
12/06/2018
Fidia Pharma Group has completed the acquisition of Sooft
The acquisition gives an added boost to Fidia’s leadership in the national and international ophthalmology market segment
• Sooft is active in the treatment of all major eye conditions through Sooft, Bioos, Glaucoom, OftaH.T.and Neoox trademarks
• The company owns 27 patents, further bolstering Fidia Pharma Group’s already strong portfolio, consisting of more than 1,100 patents, of which over 700 on hyaluronic acid
Abano Terme (PD), June 11, 2018 – Fidia Pharma Group, an Italian multinational company, leader in…
25/04/2018
New Data Evaluating HYMOVIS® Effects on Cartilage Volume and Type II Collagen Turnover at OARSI World Congress Meeting
Poster Title: “Hyaluronan Derivative Hymovis® Increases Cartilage Volume and Type II Collagen Turnover in Osteoarthritis Knee:
Data from MOKHA (MRI, BiOmarkers, Knee, Hymovis®, OsteoArthritis) Study”
• Potential beneficial effect of HYMOVIS® on pain and function
• Structural modifying effect in knee OA with HYMOVIS®
Abano Terme, Italy, April 25, 2018 – Fidia Farmaceutici, a world leader in the research, development…
09/03/2018
FIDIA ANNOUNCES PRESENTATION OF NEW DATA ON A CARTILAGE EXPLANT MODEL AT ORTHOPAEDIC RESEARCH SOCIETY (ORS) ANNUAL MEETING
Poster Title: Articular Cartilage Lubrication by HYADD®4 Reduces Tissue Strains, Chondrocyte Death, and Apoptosis
“This current study is consistent with the idea that hyaluronic acid therapies for arthritis may act in part through a mechanical pathway that preserves viability of chondrocytes at the cartilage surface,” states Dr. Bonassar.*
Florham Park, NJ, March 9, 2018 – Fidia Farmaceutici, a world leader in the research, development…
